In response to the comment by Hechler .: Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.
作者信息
Stivala Simona, Gobbato Sara, Infanti Laura, Reiner Martin F, Bonetti Nicole, Meyer Sara C, Camici Giovanni G, Lüscher Thomas F, Buser Andreas, Beer Juerg H
机构信息
Laboratory for Platelet Research, Center for Molecular Cardiology, University of Zurich, Switzerland.
Regional Service of the Swiss Red Cross, University Hospital Basel, Switzerland.
出版信息
Haematologica. 2017 Dec;102(12):e504-e505. doi: 10.3324/haematol.2017.181818.
Abstract
摘要
相似文献
1
In response to the comment by Hechler .: Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.
Haematologica. 2017 Dec;102(12):e504-e505. doi: 10.3324/haematol.2017.181818.
2
Amotosalen/UVA pathogen inactivation technology reduces platelet activability, induces apoptosis and accelerates clearance.
Haematologica. 2017 Dec;102(12):e502-e503. doi: 10.3324/haematol.2017.180539.
3
Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.
Haematologica. 2017 Oct;102(10):1650-1660. doi: 10.3324/haematol.2017.164137. Epub 2017 Jul 20.
4
Pathogen reduction with amotosalen/UVA reduces platelet refractoriness in a dog platelet transfusion model.
Vox Sang. 2019 Aug;114(6):595-604. doi: 10.1111/vox.12818. Epub 2019 Jul 11.
5
The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
Blood Rev. 2014 Nov;28(6):235-41. doi: 10.1016/j.blre.2014.07.005. Epub 2014 Aug 24.
6
Prevention of transfusion-associated graft-versus-host disease with pathogen-reduced platelets with amotosalen and ultraviolet A light: a review.
Vox Sang. 2017 Oct;112(7):607-613. doi: 10.1111/vox.12558. Epub 2017 Aug 18.
7
Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
BioDrugs. 2003;17(1):66-8. doi: 10.2165/00063030-200317010-00006.
8
Inactivation of Zika virus in platelet components using amotosalen and ultraviolet A illumination.
Transfusion. 2017 Aug;57(8):2016-2025. doi: 10.1111/trf.14161. Epub 2017 Jul 3.
9
Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients.
Vox Sang. 2017 Apr;112(3):249-256. doi: 10.1111/vox.12489. Epub 2017 Feb 15.
10
In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using amotosalen.
Vox Sang. 2004 Apr;86(3):201-2. doi: 10.1111/j.0042-9007.2004.00417.x.
引用本文的文献
1
Increase of Phosphoprotein Expressions in Amotosalen/UVA-Treated Platelet Concentrates.
Transfus Med Hemother. 2024 Feb 9;51(2):101-110. doi: 10.1159/000535060. eCollection 2024 Apr.
本文引用的文献
1
Evaluation of soluble glycoprotein V as an in vitro quality marker for platelet concentrates: a correlation study between in vitro platelet quality markers and the effect of storage medium.
Vox Sang. 2016 Aug;111(2):120-6. doi: 10.1111/vox.12402. Epub 2016 Apr 6.
2
Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro.
Vox Sang. 2015 May;108(4):328-39. doi: 10.1111/vox.12231. Epub 2014 Dec 30.
3
In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system.
Transfus Med. 2013 Apr;23(2):121-9. doi: 10.1111/tme.12020. Epub 2013 Mar 11.
4
Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation.
Transfusion. 2013 Jun;53(6):1187-200. doi: 10.1111/j.1537-2995.2012.03923.x. Epub 2012 Oct 15.
5
Drug-induced thrombocytopenia: development of a novel NOD/SCID mouse model to evaluate clearance of circulating platelets by drug-dependent antibodies and the efficacy of IVIG.
Blood. 2010 Sep 16;116(11):1958-60. doi: 10.1182/blood-2010-02-268326. Epub 2010 Jun 21.
6
Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
Br J Haematol. 2010 Jul;150(2):209-17. doi: 10.1111/j.1365-2141.2010.08227.x. Epub 2010 May 9.
7
Human platelets circulating in mice: applications for interrogating platelet function and survival, the efficacy of antiplatelet therapeutics, and the molecular basis of platelet immunological disorders.
J Thromb Haemost. 2007 Jul;5 Suppl 1:305-9. doi: 10.1111/j.1538-7836.2007.02466.x.
8
Activation-independent, antibody-mediated removal of GPVI from circulating human platelets: development of a novel NOD/SCID mouse model to evaluate the in vivo effectiveness of anti-human platelet agents.
Blood. 2006 Aug 1;108(3):908-14. doi: 10.1182/blood-2005-07-2937. Epub 2006 Mar 28.
9
Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.
Transfusion. 2005 Sep;45(9):1443-52. doi: 10.1111/j.1537-2995.2005.00550.x.
10
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.
Blood. 2004 Sep 1;104(5):1534-41. doi: 10.1182/blood-2003-12-4443. Epub 2004 May 11.
Zotero 插件